# EDGAR Filing Document

**Accession Number:** 0001479615
**File Stem:** 0001193125-26-093921
**Filing Date:** 2026-3
**Character Count:** 46517
**Document Hash:** de24e2fc89489fcec4307e9b4c6b0c02
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-093921.hdr.sgml**: 20260305

**ACCESSION NUMBER**: 0001193125-26-093921

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 16

**FILED AS OF DATE**: 20260305

**DATE AS OF CHANGE**: 20260305

**EFFECTIVENESS DATE**: 20260305

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Silence Therapeutics plc
- **CENTRAL INDEX KEY:** 0001479615
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** X0

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-294044
- **FILM NUMBER:** 26726103

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 12 HAMMERSMITH GROVE
- **STREET 2:** OFFICE 205
- **CITY:** LONDON
- **PROVINCE COUNTRY:** X0
- **ZIP:** W6 7AP
- **BUSINESS PHONE:** 44-0-20-3457 6900

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 12 HAMMERSMITH GROVE
- **STREET 2:** OFFICE 205
- **CITY:** LONDON
- **PROVINCE COUNTRY:** X0
- **ZIP:** W6 7AP

**As filed with the Securities and Exchange Commission on March 5, 2026**

**Registration No. 333-** 

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM S-8**

**REGISTRATION STATEMENT**

***UNDER***

***THE SECURITIES ACT OF 1933***

## Silence Therapeutics plc
**(Exact name of registrant as specified in its charter)**

---

| | |
|:---|:---|
| **England and Wales** | **Not applicable** |
| **(State or other jurisdiction of**<br> **incorporation or organization)** | **(I.R.S. Employer**<br> **Identification No.)** |
| **12 Hammersmith Grove**<br> **London, United Kingdom** | **W6 7AP** |
| **(Address of Principal Executive Offices)** | **(Zip code)** |

---

**Silence Therapeutics plc 2023 Equity Incentive Plan with Non-Employee Sub-Plan and CSOP Sub-Plan** 

**(Full titles of the plans)**

**Silence Therapeutics Inc.** 

**221 River Street, 9th Floor** 

**Hoboken, New Jersey 07030** 

**(Name and address of agent for service)** 

**908-938-4221** 

**(Telephone number, including area code, of agent for service)** 

***Copies to:***

---

| | |
|:---|:---|
| **Divakar Gupta**<br> **Courtney T. Thorne**<br> **Eric Blanchard**<br> **Cooley LLP**<br> **55 Hudson Yards**<br> **New York, New York 10001**<br> **+1 212 479 6000** | **Claire A. Keast-Butler**<br> **Cooley (UK) LLP**<br> **22 Bishopsgate**<br> **London EC2N 4BQ**<br> **United Kingdom**<br> **+44 (0) 20 7583 4055** |

---

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
| Emerging growth company | ☐ |  |  |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

------

**REGISTRATION OF ADDITIONAL SHARES PURSUANT TO GENERAL INSTRUCTION E**

Pursuant to General Instruction E to Form S-8, Silence Therapeutics plc (the "Registrant") is filing this Registration Statement on Form S-8 with the U.S. Securities and Exchange Commission (the "Commission") to register 2,834,037 additional ordinary shares, nominal value £0.05 per share (the "Ordinary Shares"), of the Registrant under the Silence Therapeutics plc 2023 Equity Incentive Plan with Non-Employee Sub-Plan and CSOP Sub-Plan (the "2023 Plan"), pursuant to the provisions of the 2023 Plan providing for an automatic increase in the number of Ordinary Shares reserved and available for issuance under the 2023 Plan on January 1, 2026. In accordance with the instructional note to Part I of Form S-8 as promulgated by the Commission, the information specified by Part I of the Form S-8 has been omitted from this Registration Statement.

**PART II**

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

**Item 3.** **Incorporation of Documents By Reference.** <br>

The following documents, which have been filed with the Commission by the Registrant are hereby incorporated by reference into this Registration Statement:

(a) The Registrant's Registration Statements on Form S-8, filed with the Commission on September 9, 2020 ([File No. 333-248682](http://www.sec.gov/Archives/edgar/data/1479615/000156459020042935/ck0001479615-s8.htm)), August 1, 2023 ([File No. 333-273576](http://www.sec.gov/Archives/edgar/data/1479615/000095017023036510/silience_-_s-8_june_2023.htm)) and February 27, 2025 ([File No. 333-285375](http://www.sec.gov/Archives/edgar/data/1479615/000119312525039417/d925240ds8.htm)).

(b) the Registrant's Annual Report on [Form 10-K](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001479615/000119312526092591/sln-20251231.htm) for the fiscal year ended December 31, 2025, filed with the Commission on March 5, 2026.

(c) the descriptions of the Registrant's American Depositary Shares and Ordinary Shares contained in the Registrant's Registration Statement on [<u>Form 8-A</u>](http://www.sec.gov/Archives/edgar/data/1479615/000095012320009487/ck0001479615-8k_20200902.htm) filed on September 2, 2020 (File No. 001-39487) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), including any amendment or report filed for the purpose of updating such description, including [Exhibit 4.3](http://www.sec.gov/Archives/edgar/data/1479615/000095017025029129/sln-ex4_3.htm) to the Registrant's Annual Report on [Form 10-K](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001479615/000095017025029129/sln-20241231.htm) for the fiscal year ended December 31, 2024, filed with the Commission on February 27, 2025.

(d) All other reports and documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items) on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of the filing of such reports and documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained or incorporated by reference herein or in any subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

------

---

| | |
|:---|:---|
| **Item 8** | **Exhibits.** |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Exhibit**<br> **Number** | **Description of Exhibit** | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** | **Filed<br>Herewith** |
| **Exhibit**<br> **Number** | **Description of Exhibit** | **Form** | **File No.** | **Exhibit** | **Filing Date** | **Filed<br>Herewith** |
| 4.1 | [Amended and Restated Articles of Association of Silence Therapeutics plc](http://www.sec.gov/Archives/edgar/data/1479615/000095017025104593/sln-ex3_1.htm) | 10-Q | 001-39487 | 3.1 | 8/7/2025 |  |
| 4.2 | [Deposit Agreement, by and among the registrant and The Bank of New York Mellon and the Owners and Holders of American Depositary Shares, dated September 4, 2020](http://www.sec.gov/Archives/edgar/data/1479615/000095012321003321/sln-ex41_266.htm) | F-1 | 333-254021 | 4.1 | 3/9/2021 |  |
| 4.3 | [Form of American Depositary Receipt (included in Exhibit 4.2)](http://www.sec.gov/Archives/edgar/data/1814079/000101915520000240/silence424.htm) | F-1 | 333-254021 | 4.2 | 3/9/2021 |  |
| 5.1 | [Opinion of Cooley (UK) LLP](d113552dex51.htm) |  |  |  |  | X |
| 23.1 | [Consent of PricewaterhouseCoopers LLP, the registrant's independent registered public accounting firm](d113552dex231.htm) |  |  |  |  | X |
| 23.2 | [Consent of Cooley (UK) LLP (included in Exhibit 5.1)](d113552dex51.htm) |  |  |  |  | X |
| 24.1 | [Power of Attorney (included on signature page to this registration statement)](#sig) |  |  |  |  | X |
| 99.1 | [Silence Therapeutics plc 2023 Equity Incentive Plan with Non-Employee Sub-Plan and CSOP Sub-Plan](http://www.sec.gov/Archives/edgar/data/1479615/000095017024030519/sln-ex4_10.htm) | 20-F | 001-39487 | 4.10 | 3/13/2024 |  |
| 107 | [Filing Fee Table](d113552dexfilingfees.htm) |  |  |  |  | X |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of London, United Kingdom, on the 5th day of March, 2026.

---

| | |
|:---|:---|
| **SILENCE THERAPEUTICS PLC** | **SILENCE THERAPEUTICS PLC** |
| By: | /s/ Iain Ross |
| Iain Ross | Iain Ross |
| Interim Principal Executive Officer and Chairman of the Board of Directors | Interim Principal Executive Officer and Chairman of the Board of Directors |

---

**POWER OF ATTORNEY**

KNOW ALL BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Iain Ross and Rhonda Hellums, and each or any one of them, his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his or her substitutes or substitute, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ Iain Ross<br> Iain Ross | Interim Principal Executive Officer and<br>Chairman of the Board of Directors<br>(*Principal Executive Officer*) | March 5, 2026 |
| /s/ Rhonda Hellums<br> Rhonda Hellums | Chief Financial Officer and Director<br> (*Principal Financial Officer and Principal Accounting Officer*) | March 5, 2026 |
| /s/ Dave Lemus<br> Dave Lemus | Director | March 5, 2026 |
| /s/ Tim McInerney<br> Tim McInerney | Director | March 5, 2026 |
| /s/ James Ede-Golightly<br> James Ede-Golightly | Director | March 5, 2026 |

---

------

**SIGNATURE OF AUTHORIZED U.S. REPRESENTATIVE** 

Pursuant to the Securities Act of 1933, the undersigned, the duly authorized representative in the United States of Silence Therapeutics Inc., has signed this registration statement or amendment thereto on March 5, 2026.

---

| | |
|:---|:---|
| **SILENCE THERAPEUTICS INC.** | **SILENCE THERAPEUTICS INC.** |
| By: | /s/ Rhonda Hellums |
| Name: Rhonda Hellums | Name: Rhonda Hellums |
| Title: Authorized Signatory | Title: Authorized Signatory |

---

## Exhibit 5.1

**Exhibit 5.1**![LOGO](g113552dsp10a.jpg)

Claire Keast-Butler <br> +44 (0) 20 7556 4211 ckeastbutler@cooley.com

Silence Therapeutics plc

27 Eastcastle Street

London W1W 8DH

United Kingdom

5 March 2026

Ladies and Gentlemen:

---

| | |
|:---|:---|
| **Re:** | **Silence Therapeutics plc – Registration Statement on Form S-8 – Exhibit 5.1**  |

---

**1.** **INTRODUCTION** 

1.1 We have acted as English legal advisers to Silence Therapeutics plc, a public limited company incorporated in
England and Wales (the "**Company** "), in relation to the preparation and filing of the registration statement on Form S-8 to which this opinion letter is attached as an exhibit (such
registration statement, as amended, including the documents incorporated by reference therein, the "**Registration Statement**") filed with the United States Securities and Exchange Commission (the "**SEC**") pursuant
to the United States Securities Act of 1933, as amended (the "**Securities Act**") and the rules and regulations promulgated thereunder.

1.2 The Company is filing the Registration Statement to register 2,834,037 ordinary shares of nominal value
£0.05 each in the capital of the Company ()"**Ordinary Shares** ", and such Ordinary Shares being the "**Shares**") that will be allotted and issued upon the exercise of options and/or the settlement of awards
granted or to be granted pursuant to the provisions of the Silence Therapeutics plc 2023 Equity Incentive Plan with Non-Employee Sub-Plan and CSOP Sub-Plan adopted by the board of directors (the "**Board**" or the "**Directors**") on 20 March 2023 and approved by the Company's shareholders on 27 April 2023 (the
" **2023 Equity Plan**") which provides for an automatic increase in the number of Ordinary Shares reserved and available for issuance under the 2023 Equity Plan on 1 January 2026.

1.3 We are rendering this letter at the request of the Company in connection with the Registration Statement. We
have taken instructions solely from the Company.

1.4 Except as otherwise defined in this letter, capitalised terms used have the respective meanings given to them
in the Registration Statement (as defined above) and headings are for ease of reference only and shall not affect interpretation.

1.5 All references to legislation in this letter are to the legislation of England unless the contrary is
indicated, and any reference to any provision of any legislation shall include any amendment, modification, re-enactment or extension thereof, as in force on the date of this letter.

**2.** **DOCUMENTS** 

For the purpose of issuing this letter, we have reviewed the following documents only:

2.1 a PDF copy of the draft Registration Statement to be filed with the SEC on 5 March 2026;

2.2 a PDF copy of the 2023 Equity Plan;

Cooley (UK) LLP 22 Bishopsgate London EC2N 4BQ, UK

t: +44 (0) 20 7583 4055 f: +44 (0) 20 7785 9355 cooley.com

Cooley (UK) LLP is a limited liability partnership and is registered in England and Wales with registered number OC395270. Our registered office is at the address above. Cooley (UK) LLP is authorised and regulated by the Solicitors Regulation Authority (SRA number 617791). A list of the members of Cooley (UK) LLP and their professional qualifications is open to inspection at its registered office. The word 'partner,' used in relation to Cooley (UK) LLP, refers to a member of Cooley (UK) LLP or an employee or consultant of Cooley (UK) LLP (or any affiliated firm) of equivalent standing.

------

Page Two

2.3 a PDF copy of the executed written resolutions of the Board passed on 20 March 2023 approving, *inter alia*, the 2023 Equity Plan and the delegation of authority to the remuneration committee of the Company (the "**Remuneration Committee**") (the "**Board Written Resolutions** ");

2.4 a PDF copy of the executed resolutions passed at the annual general meeting of the Company held on
27 April 2023 at which it was resolved, inter alia, to (i) approve the 2023 Equity Plan, (ii) authorise the Directors for the purposes of section 551 of the Companies Act 2006 (the "**Companies Act**") to allot shares
in the Company and grant rights to subscribe for, or convert any security into, shares in the Company up to a maximum aggregate nominal amount of £5,402,633.25 and (iii) empower the Directors to allot equity securities (as defined in
section 560 of the Companies Act) for cash pursuant to the authority referred to in (ii) as if section 561(1) of the Companies Act did not apply to such allotment (the "**Shareholder Resolutions** ");

2.5 a PDF copy of the certificate of incorporation of the Company dated 18 November 1994, a PDF copy of the
certificate of incorporation on change of name of the Company dated 21 June 1999 and a PDF copy of the certificate of incorporation on change of name of the Company dated 26 April 2007; and

2.6 a PDF copy of the current articles of association of the Company adopted on 26 June 2025 (the
" **Articles** ").

**3.** **SEARCHES** 

In addition to examining the documents referred to in paragraph 2 (*Documents*), we have carried out the following searches only:

3.1 an online search at Companies House in England and Wales ()"**Companies House**") with respect to
the Company, carried out at 09:40 a.m. (London time) on 5 March 2026 (the "**Companies House Search** "); and

3.2 an online enquiry of the Central Registry of Winding-up Petitions at
the Insolvency and Companies List in England and Wales (the "**Central Registry**") with respect to the Company, carried out at 10:00 a.m. (London time) on 5 March 2026 (the "**Central Registry Enquiry**" and, together
with the Companies House Search, the "**Searches** ").

**4.** **OPINION** 

Subject to the assumptions set out in paragraph 5 (*Assumptions*), the scope of the opinion set out in paragraph 6 (*Scope of Opinion*) and the reservations set out in paragraph 7 (*Reservations*), and subject further to the following:

4.1 the Registration Statement, as finally amended, having become effective under the Securities Act;

4.2 the delegations of authority to the Remuneration Committee having been validly effected (among other things, in
accordance with article 120 of the Articles, the 2023 Equity Plan and applicable laws);

4.3 the Directors or the Remuneration Committee (including the Chair of the Remuneration Committee, as applicable)
having validly granted the awards in respect of the Shares under the 2023 Equity Plan;

4.4 the Directors or the Remuneration Committee having validly resolved to allot and issue the Shares, or grant
rights to subscribe for the Shares, at duly convened and quorate meetings of the Board or the Remuneration Committee, or by way of duly passed written resolutions of the Board or the Remuneration Committee in compliance with all applicable laws and
regulations and with such resolutions being in full force and effect and not having been rescinded or amended;

------

Page Three

4.5 the receipt in full of payment for the Shares in an amount of "cash consideration" (as defined in
section 583(3) of the Companies Act) of not less than the aggregate nominal value and any premium thereon for such Shares, assuming in each case that the individual grants or awards under the 2023 Equity Plan are duly authorised by all necessary
corporate action and duly granted or awarded and exercised in accordance with the requirements of applicable law, the Articles and the 2023 Equity Plan (and the agreements and awards duly adopted thereunder and in accordance therewith); and

4.6 valid entries having been made in relation to the allotment and issue of the Shares in the books and registers
of the Company,

it is our opinion that, as at today's date, the Shares, if and when allotted and issued, registered in the name of the recipient in the register of members of the Company and delivered in accordance with the terms and conditions referred to in the 2023 Equity Plan and as described in the Registration Statement, will be duly and validly authorised and issued, fully paid or credited as fully paid (subject to the receipt of valid consideration by the Company for the issue thereof) and will not be subject to any call for payment of further capital.

**5.** **ASSUMPTIONS** 

In giving the opinion in this letter, we have assumed (without making enquiry or investigation) that:

5.1 all signatures, stamps and seals on all documents are genuine. All original documents are complete, authentic
and up-to-date, and all documents submitted to us as a copy (whether by email or otherwise) are complete and accurate and conform to the original documents of which they
are copies and that no amendments (whether oral, in writing or by conduct of the parties) have been made to any of the documents since they were examined by us;

5.2 where a document has been examined by us in draft or specimen form, it will be or has been duly executed in the
form of that draft or specimen;

5.3 the Articles referred to in paragraph 2.6 (*Documents*) of this letter remain in full force and effect,
and no alteration has been made or will be made to the Articles, in each case prior to the relevant date of the granting of rights to subscribe for the Shares and/or the allotment and issue of the Shares (each such date, an "**Allotment Date** ");

5.4 at the time of each allotment and issue of any Shares the Company shall have received in full "cash
consideration" (as such term is defined in section 583(3) of the Companies Act) equal to the subscription price payable for such Shares and shall have entered the holder or holders thereof in the register of members of the Company showing that
all such Shares shall have been fully paid up as to their nominal value and any premium thereon as at each Allotment Date;

5.5 the 2023 Equity Plan has been validly adopted and remains in full force and effect, and no alterations have
been made or will be made to the 2023 Equity Plan prior to any Allotment Date;

5.6 in relation to any allotment and issue of any Shares by the Company pursuant to the 2023 Equity Plan, the
recipient shall have become entitled to such Shares under the terms of the 2023 Equity Plan and such Shares, or rights over Shares, where applicable, will be fully vested each in accordance with the terms of the 2023 Equity Plan, and such recipient
has or will have complied with all other requirements of the 2023 Equity Plan in connection with the allotment and issue of such Shares;

5.7 all awards have been or will be made under the terms of the 2023 Equity Plan, that the terms of all awards have
not materially deviated or will not materially deviate from the terms set out in the 2023 Equity Plan, and that any Shares will be allotted and issued in accordance with the terms set out in the 2023 Equity Plan and in accordance with the Articles
and applicable laws;

5.8 the 2023 Equity Plan (other than the Non-Employee Sub-Plan) qualifies as an "employees' share scheme" as defined in section 1166 of the Companies Act;

------

Page Four

5.9 immediately prior to each Allotment Date, the Directors had or shall have sufficient authority and powers
conferred upon them to allot and issue such Shares and grant such rights (as applicable) under section 551 of the Companies Act (unless such allotment and issue or grant was or is exempt under section 549(2) of the Companies Act) and under section
570 or section 571 of the Companies Act as if section 561 of the Companies Act did not apply to such allotment and issue or grant (unless such allotment and issue or grant was or is exempt from section 561 of the Companies Act pursuant to section
566 of the Companies Act) pursuant to the Shareholder Resolutions, and the Directors have not and shall not allot or issue (or purport to allot or issue) Shares and have not and shall not grant rights (or purport to grant rights) to acquire Shares
in excess of such powers or in breach of any other limitation on their power to allot and issue Shares or grant rights to acquire Shares;

5.10 no Shares shall be allotted or issued, or are or shall be committed to be allotted or issued, at a discount to
their nominal value (whether in dollars or equivalent in any other currency);

5.11 all documents, forms and notices which should have been delivered to Companies House in respect of the Company
have been so delivered;

5.12 the information revealed by the Searches is true, accurate, complete and up-to-date in all respects, and there is no information which should have been disclosed by the Searches that has not been disclosed for any reason and there has been no alteration in the status or condition
of the Company since the date and time that the Searches were made and that the results of the Searches will remain complete and accurate as at each Allotment Date;

5.13 in relation to the allotment and issue of the Shares, the Directors have acted and will act in the manner
required by section 172 of the Companies Act and the Shares will be allotted and issued in good faith and on bona fide commercial terms and on arms' length terms and for the purpose of carrying on the business of the Company and that there are
reasonable grounds for believing that the allotment and issue of the Shares will promote the success of the Company for the benefit of its members as a whole;

5.14 there has not been and will not be any bad faith, breach of trust, fraud, coercion, duress or undue influence
on the part of any of the Directors in relation to any allotment and issue of Shares;

5.15 the resolutions set out in the Board Written Resolutions referred to in paragraph 2.3 (*Documents*) were
validly passed as written resolutions in accordance with the articles of association of the Company in effect at such time, that all eligible Directors (being all the Directors who would have been entitled to vote on the matter had it been proposed
as a resolution at a Directors' meeting, but excluding any Director whose vote is not to be counted in respect of a particular matter) signed one or more copies of the Board Written Resolutions, that all relevant provisions of the Companies
Act and the articles of association of the Company in effect at such time were complied with and were duly observed (including, if applicable, those relating to the declaration of each Director's interests or their power to vote) and such
resolutions were duly adopted, and have not been revoked or varied and remain in full force and effect and will remain so as at each Allotment Date;

5.16 any written resolutions of the Directors or the Remuneration Committee referred to in paragraph 4.4 of this
letter will be validly passed as written resolutions in accordance with the articles of association of the Company in effect as at such time, that all eligible Directors (being all the Directors who would have been entitled to vote on the matter had
it been proposed as a resolution at a Directors' meeting, or a meeting of the Remuneration Committee, as applicable, but excluding any Director whose vote is not to be counted in respect of a particular matter) will sign one or more copies of
the resolutions, that all relevant provisions of the Companies Act and the articles of association of the Company in effect at such time will be complied with and duly observed (including, if applicable, those relating to the declaration of
Directors' interests or the power of interested Directors to vote) and such resolutions will be duly adopted, and will not be revoked or varied and will remain in full force and effect once passed and will remain so as at each Allotment Date;

------

Page Five

5.17 each meeting of the Directors or the Remuneration Committee referred to in paragraph 4.4 of this letter will be
duly conducted as described therein, duly constituted and convened and all constitutional, statutory and other formalities will be duly observed (including, if applicable, those relating to the declaration of Directors' interests or the power
of interested Directors to vote), a quorum will be present throughout, the requisite majority of Directors will vote in favour of approving the resolutions and the resolutions passed at each such meeting of the Directors or the Remuneration
Committee will be duly adopted, will not be revoked or varied and remain in full force and effect once passed and will remain so as at each relevant Allotment Date;

5.18 the Shareholder Resolutions were duly passed at the annual general meeting held on 27 April 2023 at which
all constitutional, statutory and other filings were duly observed, a quorum of shareholders was present throughout and the Shareholder Resolutions referred to in paragraph 2.4 (*Documents*) were duly passed and have not been revoked or varied
and remain in full force and effect and will remain so as at each Allotment Date and all filings required to be made with Companies House in connection therewith have been made within the relevant time limits;

5.19 as at each Allotment Date, in respect of any grant or allotment that is not being made pursuant to an
employees' share scheme as defined in section 1166 of the Companies Act, the authorities granted pursuant to the Shareholder Resolutions remained or will remain unutilised to the extent necessary to permit such allotment and issue, or if at
any Allotment Date such authorities have expired or been fully utilised, the Company in general meeting having duly and validly resolved (i) as an ordinary resolution to authorise the Directors pursuant to section 551 of the Companies Act to
allot the Shares, or grant rights to subscribe for the Shares, pursuant to the 2023 Equity Plan, and (ii) as a special resolution to empower the Directors pursuant to section 570 or 571 of the Companies Act to allot such Shares and grant such
rights (as applicable), free of the restrictions in section 561 of the Companies Act;

5.20 the resolutions of the shareholders of the Company referred to in paragraph 5.19 will be duly passed as
resolutions of the Company at a duly convened and held general meeting of the Company, all constitutional, statutory and other formalities will be observed in respect of such meeting and such resolutions will not have expired and will not be revoked
or varied prior to each Allotment Date and will remain in full force and effect as at each Allotment Date;

5.21 the Company has complied and will comply with all applicable anti-terrorism, anti-money laundering, sanctions
and human rights laws and regulations and that each grant of rights to acquire Shares under the 2023 Equity Plan and that each allotment and issue of Shares pursuant to the 2023 Equity Plan will be consistent with all such laws and regulations;

5.22 no Shares or rights to subscribe for Shares have been or shall be offered to the public in the United Kingdom
in breach of the Financial Services and Markets Act 2000 ()"**FSMA** "), the Public Offers and Admissions to Trading Regulations 2024, or of any other United Kingdom laws or regulations concerning offers of securities to the public, and
no communication has been or shall be made in relation to the Shares in breach of section 21 (*Restrictions on financial promotion*) of FSMA or any other United Kingdom laws or regulations relating to offers or invitations to subscribe for, or
to acquire rights to subscribe for or otherwise acquire, shares or other securities;

5.23 in issuing and allotting and granting rights to acquire Shares and administering the 2023 Equity Plan, the
Company is not carrying on a regulated activity (within the meaning of section 19 (*The general prohibition*) of FSMA); and

5.24 the Company has not taken any corporate or other action nor have any steps been taken or legal proceedings been
started against the Company for the liquidation, winding-up, dissolution or reorganisation of, or for the appointment of a liquidator, receiver, trustee, administrator, administrative receiver or similar
officer of, any such party (including the Company) or all or any of its or their assets (or any analogous proceedings in any jurisdiction) and no such steps or proceedings will have been taken as at each Allotment Date, and the Company is not unable
to pay its debts as they fall due within the meaning of section 123 of the Insolvency Act 1986, as amended (the "**Insolvency Act**") and will not become unable to pay its debts within the meaning of that section as a result of any of
the transactions contemplated herein, is not insolvent and has not been dissolved (although the Searches gave no indication that any winding-up, dissolution or administration order or appointment of a
receiver, administrator, administrative receiver or similar officer has been made with respect to the Company) and such actions and steps will not have been taken as at any Allotment Date.

------

Page Six

**6.** **SCOPE OF OPINION** 

6.1 The opinion given in this letter is limited to English law as it would be applied by English courts on the date
of this letter.

6.2 We express no opinion in this letter on the laws of any other jurisdiction. We have not investigated the laws
of any country other than England and we assume that no foreign law affects the opinion stated in paragraph 4 (*Opinion*).

6.3 We express no opinion as to any agreement, instrument or other document other than as specified in this letter.
For the purposes of giving the opinion in paragraph 4 (*Opinion*), we have only examined and relied on those documents set out in paragraph 2 (*Documents*) and made those searches and enquiries set out in paragraph 3 (*Searches*),
respectively. We have made no further enquiries concerning the Company or any other matter in connection with the giving of the opinion in paragraph 4 (*Opinion*).

6.4 No opinion is expressed with respect to taxation in the United Kingdom or otherwise in this letter.

6.5 We have not been responsible for investigating or verifying the accuracy of the facts or the reasonableness of
any statement of opinion or intention, contained in or relevant to any document referred to in this letter, or that no material facts have been omitted therefrom.

6.6 The opinion given in this letter is given on the basis of each of the assumptions set out in paragraph 5
(*Assumptions*) and is subject to each of the reservations set out in paragraph 7 (*Reservations*) to this letter. The opinion given in this letter is strictly limited to the matters stated in paragraph 4 (*Opinion*) and does not
extend, and should not be read as extending, by implication or otherwise, to any other matters.

6.7 This letter only applies to those facts and circumstances which exist as at today's date and we assume no
obligation or responsibility to update or supplement this letter to reflect any facts or circumstances which may subsequently come to our attention, any changes in laws which may occur after today, or to inform the addressee of any change in
circumstances happening after the date of this letter which would alter the opinion given in this letter.

6.8 We have not been responsible for investigation or verification of statements of fact (including statements as
to foreign law) or to the reasonableness of any statements of opinion in the Registration Statement, or that no material facts have been omitted therefrom.

6.9 This letter is given by Cooley (UK) LLP and no partner or employee assumes any personal responsibility for it
nor shall owe any duty of care in respect of it.

6.10 This letter, the opinion given in it, and any non-contractual obligations arising out of or in connection with this letter and/or the opinion given in it, are governed by and shall be construed in accordance with English law as at the date of this letter.

**7.** **RESERVATIONS** 

7.1 The Companies House Search described at paragraph 3.1 (*Searches*) is not capable of revealing
conclusively whether or not:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) a winding-up order has been made or a resolution passed for the winding-up of a company;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) an administration order has been made; or

------

Page Seven

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) a receiver, administrative receiver, administrator or liquidator has been appointed,

since notice of these matters may not be filed with the Registrar of Companies in England and Wales immediately and, when filed, may not be entered on the public database or recorded on the public microfiches of the relevant company immediately.

In addition, such a company search is not capable of revealing, prior to the making of the relevant order, whether or not a winding-up petition or a petition for an administration order has been presented.

7.2 The Central Registry Enquiry described at paragraph 3.2 (*Searches*) relates only to a compulsory winding-up and is not capable of revealing conclusively whether or not a winding-up petition in respect of a compulsory winding-up has
been presented, since details of the petition may not have been entered on the records of the Central Registry immediately or, in the case of a petition presented to a District Registry and/or County Court in England and Wales, may not have been
notified to the Central Registry and entered on such records at all, and the response to an enquiry only relates to the period since approximately 2016 for petitions presented in London and since approximately 2019 for petitions presented to a
District Registry and/or County Court in England and Wales. We have not made enquiries of any District Registry or County Court in England and Wales.

7.3 The opinion set out in this letter is subject to: (i) any limitations arising from applicable laws
relating to insolvency, bankruptcy, administration, reorganisation, liquidation, moratoria, schemes or analogous circumstances; and (ii) an English court exercising its discretion under section 426 of the Insolvency Act (co-operation between courts exercising jurisdiction in relation to insolvency) to assist the courts having the corresponding jurisdiction in any part of the United Kingdom or any relevant country or territory.

7.4 We express no opinion as to matters of fact.

7.5 We have made no enquiries of any individual connected with the Company.

7.6 We express no opinion on the compliance of the 2023 Equity Plan or the compliance of any award made or to be
made under the 2023 Equity Plan with the rules or regulations of the Nasdaq Global Market or the rules or regulations of any other securities exchange that are applicable to the Company.

7.7 A certificate, documentation, notification, opinion or the like might be held by the English courts not to be
conclusive if it can be shown to have an unreasonable or arbitrary basis or in the event of a manifest error.

7.8 We express no opinion in relation to the legality, enforceability or validity of the 2023 Equity Plan or any
award agreement entered into or to be entered into pursuant to the 2023 Equity Plan. In particular, but without prejudice to the generality of the foregoing, we have assumed that the Shares to be allotted under the 2023 Equity Plan or any such award
agreement will be paid up in full (as to their nominal value and any premium) in cash (within the meaning of section 583(1) of the Companies Act) and we express no opinion as to whether any consideration other than "cash consideration"
(as such term is defined in section 583(3) of the Companies Act) which might be paid, or purport to be paid, for the Shares would result in such Shares being validly issued, fully paid and not subject to any call for payment of further capital.

7.9 If (a) the Company or any person to whom the Shares are to be allotted and issued (a "**Relevant Person**") is the target of economic or financial sanctions or other restrictive measures imposed in any jurisdiction ()"**Sanctions**") or is owned or controlled (directly or indirectly) by or is acting on behalf of or at the
direction of or is otherwise connected with a person who is a target of Sanctions or (b) a Relevant Person is incorporated or resident in or operating from a country or territory that is a target of Sanctions or (c) the rights or
obligations of a Relevant Person is otherwise affected by Sanctions, then the rights and obligations of such Relevant Person under the 2023 Equity Plan may be void and/or unenforceable.

7.10 We express no opinion in this letter on the application or potential application of the National Security and
Investment Act 2021 in relation to the 2023 Equity Plan or any transaction contemplated thereby.

------

Page Eight

**8.** **DISCLOSURE AND RELIANCE** 

8.1 This letter is addressed to you solely for your benefit in connection with the Registration Statement. We
consent to the filing of this letter as an exhibit to the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under section 7 of the Securities Act or the rules and
regulations promulgated thereunder.

8.2 This letter may not be relied upon by you for any other purpose, or furnished to, assigned to, quoted to, or
relied upon by any other person, firm or other entity for any purpose, other than for the purpose set out in above in paragraph 8.1, without our prior written consent, which may be granted or withheld at our sole discretion.

Yours faithfully

/s/ Cooley (UK) LLP

**Cooley (UK) LLP**

## Exhibit 23.1

**Exhibit 23.1**![LOGO](g113552pwc.jpg)

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM** 

We hereby consent to the incorporation by reference in this Registration Statement on Form S-8 of Silence Therapeutics plc of our report dated March 05, 2026 relating to the financial statements, which appears in Silence Therapeutic plc's Annual Report on Form 10-K for the year ended December 31, 2025.

/s/PricewaterhouseCoopers LLP

Reading, United Kingdom

March 05, 2026

---

| | |
|:---|:---|
|  | **PricewaterhouseCoopers LLP, 3 Forbury Place, 23 Forbury Road,**<br> **Reading, Berkshire, RG1 3JH**<br> **+44 (0) 118 959 7111** |
| **www.pwc.com** | PricewaterhouseCoopers LLP is a limited liability partnership registered in England with registered<br>number OC303525. The registered office of PricewaterhouseCoopers LLP is 1 Embankment Place,<br>London WC2N 6RH. PricewaterhouseCoopers LLP is authorised and regulated by the Financial<br>Conduct Authority for designated investment business and the Solicitors Regulation Authority for the<br>provision of regulated legal services. |

---

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

---

| |
|:---|
| **Calculation of Filing Fee Tables**  |
| &nbsp;&nbsp;&nbsp;&nbsp;**S-8**  |
| &nbsp;&nbsp;&nbsp;&nbsp;**Silence Therapeutics plc**  |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Security Type**  | **Security Class Title**  | **Fee Calculation Rule**  | **Amount Registered**  | **Proposed Maximum Offering Price Per Unit**  | **Maximum Aggregate Offering Price**  | **Fee Rate**  | **Amount of Registration Fee**  |
| 1 | Equity | Ordinary Shares, nominal value GBP 0.05 per share, to be issued upon the exercise of options to be granted under the 2023 Equity Incentive Plan with Non-Employee Sub-Plan and CSOP Sub-Plan | Other | 2834037 | $1.79 | $5072927.00 | 0.0001381 | $700.58 |
| Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: |  | $5072927.00  |  | $700.58  |
| Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  |  |  |  | $0.00  |
| Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  |  |  |  | $700.58  |

---

 **Offering Note** <br>

<sup>1</sup> (A) These shares may be represented by the Silence Therapeutics plc (the "Registrant's") American Depositary Shares ("ADSs"). Each ADS represents three ordinary shares, nominal value GBP0.05 per share ("Ordinary Shares"). The Registrant's ADSs issuable upon deposit of the Ordinary Shares registered hereby have been registered under a separate registration statement on Form F-6 (File No. 333-248217). (B) Pursuant to Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"), this registration statement shall also cover any additional Ordinary Shares and ADSs of the Registrant that become issuable under the Registrant's 2023 Equity Incentive Plan with Non-Employee Sub-Plan and CSOP Sub-Plan (the "2023 EIP") by reason of any share dividend, share split (sub-division), recapitalization or other similar transaction. (C) Estimated in accordance with Rules 457(c) and 457(h) solely for purposes of calculating the registration fee on the basis of $1.79 per Ordinary Share (or $5.37 per ADS), the average of the high and low prices of the ADSs as reported on the Nasdaq Global Market on February 26, 2026. (D) Represents 2,834,037 additional Ordinary Shares that were add to the shares authorized for issuance under the Registrant's 2023 EIP on January 1, 2026 pursuant to an annual "evergreen" increase provision contained in the 2023 EIP. The number of shares reserved for issuance under the 2023 EIP will automatically increase on January 1st each year, starting on January 1, 2024, and continuing through January 1, 2033, by an amount which is the lesser of (a) five percent (5%) of the total number of Ordinary Shares of the Registrant outstanding on December 31st of the immediately preceding calendar year; and (b) a smaller number of shares determined by the Registrant's board of directors. Prior to January 1, 2026, the board of directors approved an annual increase equal to 2% of the aggregate number of Ordinary Shares outstanding on December 31, 2025 to the 2023 EIP, which is 2,834,037 shares.

---

| | |
|:---|:---|
| | |
| **Rule 457(p)** | **Rule 457(p)** |
| Fee Offset Claims | N/A |
| Fee Offset Sources | N/A |

---